Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) For Chronic Obstructive Pulmonary Disease

Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced the treatment of the first patients in a new Phase II clinical trial evaluating Prochymal, a mesenchymal stem cell (MSC) therapy, for moderate to severe Chronic Obstructive Pulmonary Disease (COPD). This trial marks the sixth indication for which Prochymal has been advanced into Phase II or later-stage clinical trials.

More: continued here

Filed under: Stem Cell Research on June 1st, 2008